Gensight biologics reaches agreement with ansm for opening of lumevoq® named early access program (aac) in france

Paris--(business wire)--regulatory news: gensight biologics ("gensight biologics" or the "company") (euronext: sight, isin: fr0013183985, pea-pme eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the french medicines safety agency ansm to consider expeditiously opening the french named early access program (aac) for lume.
AAC Ratings Summary
AAC Quant Ranking